You’re more than welcome to contact us. Just fill out the form bellow. And we’ll get back tou you as soon as possible.
Markus has a diversified background in the healthcare industry. Prior to Alentis, he was Chief Business Officer and member of the executive team of Ablynx NV, which was sold to Sanofi in 2018 for €3.9bn.
Prior to Ablynx, Markus was a member of the executive team at GE Healthcare, responsible for growth strategies, portfolio management, M&A, licenses, and alliances. Before GE he was Head of Strategy, BD&L, and M&A for Novartis Molecular Diagnostics and a member of its leadership team. In 2005, he joined Novartis with responsibility for Global BD&L activities in CVM. Previously, Markus was CEO of two biotech start-ups (Axxima and Xerion) and Head of International Product Management and Director of BD at Schwarz Pharma. Markus started his career at The Boston Consulting Group.
Markus holds a PhD in molecular biology from the University of Heidelberg and an MBA from the University of Chicago. He is the founder of The Healthcare Advisory and is an Entrepreneur in Residence for BioMed Partners.
Greg is a CMC expert and a product development leader with more than 25 years experience.
Prior to Alentis, Greg was VP Biologics CMC at Glenmark Pharmaceuticals, where he led a department of 75+ scientists and engineers developing and manufacturing a pipeline of multiple mAb, bispecific and biosimilar products. Prior to Glenmark he was Product Discovery/Development Department head at NovImmune and responsible for a 20+ team developing a pipeline of multiple mAb and bispecific products. Previously he was a discovery scientist at Pierre Fabre and at GSK.
Greg has a PhD in Molecular Immunology from the University of Manchester. He is the owner of GE Consulting, providing BioPharma product development solutions to a portfolio of SME and start up ventures.
Prior to Alentis, for two decades he was leading drug discovery projects from basic research through in vitro and in vivo pharmacology up to proof of concept in man, at the Novartis Institutes of BioMedical Research (NIBR), and at Boehringer Ingelheim.
Previously, Tamas was a Fogarty fellow at the NIH, was a research scientist at the Institute of Molecular Pathology (IMP) in Vienna, and had teaching appointments at the University of Vienna. He obtained his MD from the Semmelweis University Budapest, and holds a PhD in molecular immunology.
Markus has a more than 20 years experience in R&D project management in Translational Medicine. Prior to Alentis, he was Director Project Management at Curevac, Tuebingen (Germany).
Prior to Curevac, Markus was a Global Project Team Leader at Sandoz/Novartis and Global R&D Project Leader at Roche, responsible for the development of molecules to clinical proof-of-concept in the areas of CVM, ophthalmology, infectious diseases and oncology.
Markus holds a PhD in molecular biology from the University of Munich and the Max Planck Institute for Biochemistry (Martinsried) and is certified Project Management Professional (PMP).